Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

OX40 Ligand/TNFSF4 Antibody (159403) [FITC], Novus Biologicals™
SDP

Mouse Monoclonal Antibody

Supplier:  Novus Biologicals FAB10541F

Catalog No. NB401390


Only null left
Add to Cart

Description

Description

OX40 Ligand/TNFSF4 Monoclonal antibody specifically detects OX40 Ligand/TNFSF4 in Human samples. It is validated for Flow Cytometry, Neutralization, Immunocytochemistry, CyTOF
Specifications

Specifications

OX40 Ligand/TNFSF4
Monoclonal
FITC
PBS
Mouse
Protein A or G purified from hybridoma culture supernatant
RUO
Primary
Human
Purified
Flow Cytometry, Neutralization, Immunocytochemistry, CyTOF
159403
Flow Cytometry, Neutralization, Immunocytochemistry, CyTOF-ready
CD134 ligand, CD134L, CD252, CD252 antigen, Glycoprotein Gp34, gp34, OX40 antigen ligand, OX40 ligand, OX40L, OX-40L, OX4OL, TAX transcriptionally-activated glycoprotein 1, tax-transcriptionally activated glycoprotein 1 (34kD), tax-transcriptionally activated glycoprotein 1, 34kD, tumor necrosis factor (ligand) superfamily, member 4, tumor necrosis factor ligand superfamily member 4, TXGP1
Mouse myeloma cell line NS0-derived recombinant human OX40 Ligand, Gln51-Leu183, Accession # P23510
0.1 mL
Cancer, Cell Cycle and Replication, Immunology
7292
Store at 4°C in the dark.
IgG1
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.